Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04319276 · ClinicalTrials.gov registry record · Phase 1
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
A Phase 1 study of Glioblastoma, sponsored by Medical College of Wisconsin.
- Active
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT04319276: Active Phase 1 study of Glioblastoma, sponsored by Medical College of Wisconsin.
NCT04319276 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by Medical College of Wisconsin. The registered enrollment target is 26 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04319276, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by Medical College of Wisconsin.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).
Primary Outcome
This will be determined from the incidence of dose limiting toxicities at each dosage.
Conditions Studied
Interventions
- DRUG Gallium maltolate (500 mg)
- DRUG Gallium maltolate (1,000 mg)
- DRUG Gallium maltolate (1,500 mg)
- DRUG Gallium maltolate (2,000 mg)
- DRUG Gallium maltolate (2,500 mg)
Study Locations (1)
Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 1 |
What the registry record for NCT04319276 still lists
NCT04319276 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Gallium maltolate (500 mg) is the first listed.
NCT04319276 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04319276 about?
NCT04319276 is a clinical study titled "Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma". This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).
What is the current status of trial NCT04319276?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2022-11-11. Estimated completion is 2027-03-01.
What conditions does trial NCT04319276 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT04319276?
The interventions under investigation include: Gallium maltolate (500 mg) (DRUG), Gallium maltolate (1,000 mg) (DRUG), Gallium maltolate (1,500 mg) (DRUG), Gallium maltolate (2,000 mg) (DRUG), Gallium maltolate (2,500 mg) (DRUG).
Who is sponsoring clinical trial NCT04319276?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04319276 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04319276's enrollment target sits among peer trials
26 137th of 199 higher than 63 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI